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Abstract The potential role of antibodies and T lympho-
cytes in the eradication of cancer has been demonstrated in
numerous animal models and clinical trials. In the last
decennia new strategies have been developed for the use of
tumor-speciWc T cells and antibodies in cancer therapy.
EVective anti-tumor immunotherapy requires the identiWca-
tion of suitable target antigens. The expression of tumor-
speciWc antigens has been extensively studied for most
types of adult tumors. Pediatric patients should be excellent
candidates for immunotherapy since their immune system
is more potent and Xexible as compared to that of adults. So
far, these patients do not beneWt enough from the pro-
gresses in cancer immunotherapy, and one of the reasons is
the paucity of tumor-speciWc antigens identiWed on pediat-
ric tumors. In this review we discuss the current status of
cancer immunotherapy in children, focusing on the identiW-
cation of tumor-speciWc antigens on pediatric solid tumors.
Keywords Antigen · Cancer · Immunotherapy · Pediatrics
Introduction
Despite major advances in the treatment of childhood
malignancies, cancer remains in the developed world the
second most common cause of death for children >1 year of
age [76]. Children and adolescents with primary multifocal,
refractory, or relapsed malignant solid tumors still have a
poor prognosis. Moreover, most cancer therapies are asso-
ciated with signiWcant toxicity leading to long-term mor-
bidity and an increased second malignancy rate [75, 135].
Therefore, new treatment strategies are warranted. One of
them is immunotherapy, in which the patient’s own
immune system is mobilized to Wght the cancer in a speciWc
way, thereby causing only mild toxicity [101].
The immune system can reject tumors
Early studies in mice showed that the immune system can
recognize and reject tumors [39]. Numerous mouse tumor
models have been developed to identify which part of the
immune system is responsible for the eradication of tumors.
These studies indicate that both CD8+ and CD4+ T cells
play a critical role in tumor rejection or in inhibition of
tumor growth [13]. The cytolytic activity of CD8+ T cells
exerts a direct anti-tumor eVect [66]. CD4+ T cells partici-
pate through the activation and maintenance of CD8+ T
cells and the recruitment of inXammatory cells such as
macrophages, granulocytes, natural killer (NK) cells, and B
cells [24, 47, 51, 93, 131].
Tumor-inWltrating immune cells have frequently been
observed in a wide variety of pediatric tumors [103, 125].
Tumor inWltration of lymphocytes is generally associated
with a more favorable prognosis and occasionally tumor
regression [34, 119]. Another element is the observation
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are at higher risk to develop cancer [36, 89]. Initial studies
have consistently shown a role of the immune system in the
prevention of virally induced cancers in adults such as
Kaposi’s sarcoma (linked with human herpes virus 8), cer-
vix carcinoma (human papilloma virus), and hepatocellular
carcinoma (hepatitis B and C) [96] but also in children with
certain lymphomas (induced by the Epstein-Barr virus) [42,
114]. These data suggest that the immune system plays an
important role in preventing or controlling malignancy in
both adults and children. In spite of the blood-brain-barrier
and lack of conventional lymphatics in the brain, there is
accumulating evidence that even brain tumors can cause
immune activation [10, 72, 99].
Immunotherapy strategies in pediatric cancer patients
Immunotherapy can be deWned as any approach that
seeks to mobilize or manipulate the immune system of a
patient for therapeutic beneWt (Fig. 1) [61, 116]. Clinical
experience of immunotherapy in the pediatric oncological
setting has been gained in treating hematologic malignan-
cies with allogeneic bone marrow transplantations and
infusions of donor lymphocytes to generate graft versus
leukemia responses [98]. Other clinical trials for pediat-
ric patients have involved general immunostimulation
with cytokines such as IL-2, TNF-, and IFN-, as adju-
vant therapies to eradicate minimal residual disease [62,
112, 123, 133]. Immunotherapeutic therapies targeting
identiWed tumor-associated antigens are discussed in the
following.
Antibodies
The identiWcation of tumor-speciWc cell-surface molecules
opened the possibility for antibody-mediated passive
immunotherapy. Antibodies (Ab) against tumor-associated
antigens can induce complement dependent cytotoxicity
(CDC) and Ab-dependent cell-mediated cytotoxicity
(ADCC) [70]. Promising pediatric clinical phase I trials
have been described using monoclonal Ab against ganglio-
sides, which are highly expressed in neuroblastoma
and osteosarcoma [40, 87, 88, 128]. Tumor-speciWc Ab
Fig. 1 Immunotherapeutic strategies applied in pediatric clinical
trials. A Administration of tumor antigens either directly into the body
or loaded onto APC. The TAAs are presented by the APC to lympho-
cytes in secondary lymphoid organs to initiate a tumor-speciWc im-
mune response. B Non-speciWc stimulation of the immune response by
cytokines, for example IL-2, TNF- and IFN- and GM-CSF which
induces T cell proliferation. C Adoptive transfer of donor lymphocytes
or natural killer cells for complete eradication of leukemic cells
following allogeneic transplantation. D  Monoclonal antibodies (mAb)
that bind speciWcally to cancer cells can induce an immune response.
Alternatively, mAb can be modiWed for targeted delivery of a toxin,
radioisotope, cytokine, or other active conjugate. TAA tumor-associ-
ated antigens, APC antigen-presenting cell, PBL peripheral blood lym-
phocyte, CDC complement dependent cytotoxicity, ADCC antibody
dependent cell-mediated cytotoxicity
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drug-vehicles for embryonal tumors [86, 105].
Adoptive cellular immunotherapy
Reconstituting or increasing cellular immunity can be
achieved through the infusion of tumor-speciWc T cells.
Autologous CD4+ or CD8+ T cells can be manipulated
ex vivo in various ways to obtain high numbers of clinical
grade tumor-speciWc T cells [23]. The therapeutic eVect of
infused tumor-speciWc T cells depends on the viability of
the cells, their homing to the tumor, and their ability to kill
within the tumor microenvironment.
Another aspect is the renewed appreciation of the role of
the innate immune system. Immune-mediated tumor lysis is
the result of a combined action of adaptive and innate
immunity, in which NK cells are important eVector cells.
NK cell activation is regulated by a balance between sig-
nals mediated through activating receptors such as NKG2D
and inhibitory receptors such as killer immunoglobulin-like
receptors (KIRs). Upon cellular transformation in tumor
cells, MHC class I ligands for inhibitory receptors are often
downregulated and ligands for activating NK cell receptors
are upregulated on the tumor cell. Together, these events
can shift the balance toward NK-mediated tumor-cell kill-
ing [78]. Next to the direct cytotoxic eVect on tumor cells,
NK cells produce type I interferons that create a proinXam-
matory tumor microenvironment [106, 113]. Clinical stud-
ies on adoptive transfer of NK cells in adults have shown
that NK cells can have a role in the treatment of selected
malignancies [84]. Adoptive transfer of NK cells in pediat-
ric patients with leukemia is feasible [68]. Ongoing clinical
studies further investigate NK cell-mediated immunother-
apy for pediatric patients with leukemia or neuroblastoma
(http://www.clinicaltrials.gov).
In vivo induction of tumor-speciWc lymphocytes
The advantage of active immunization over adoptive trans-
fer is the possibility of inducing memory T cells that can
control tumor relapse [37]. On the basis of the successes of
attenuated pathogen vaccines and owing to the initial lack
of deWned tumor antigens, the Wrst active immunizations
were carried out with whole tumor cells that were previ-
ously irradiated or otherwise inactivated [134]. In children,
most of the clinical experience using whole tumor cell vac-
cines is obtained with neuroblastoma patients. In these tri-
als, the neuroblastoma cells are (gene-) modiWed to express
various co-stimulatory molecules or cytokines to increase
their immunogenicity [9, 16, 107].
When tumor-associated antigens are identiWed, thera-
peutic vaccination can involve the administration of the
antigen either as a whole recombinant protein or as
antigenic peptides presented by HLA class I or class II mol-
ecules. One clinical trial reports on using chimeric anti-
genic peptides encoded by translocated genes expressed in
Ewing’s sarcoma and rhabdomyosarcoma [26]. Another
strategy is the administration of autologous antigen-pre-
senting cells, such as dendritic cells, loaded with deWned
tumor antigens or with tumor cell lysates. We reported that
clinical grade dendritic cells can be cultured from blood
monocytes of pediatric cancer patients [55]. Others have
reported that such dendritic cells can induce tumor-speciWc
T cells that can cause regression of high-risk malignancies
in pediatric patients [19, 29, 30, 43].
Advances in gene transfer technology have added new
possibilities to optimize vaccine preparation [74, 94]. These
include transferring genes encoding pro-inXammatory pro-
teins to tumor cells and transferring tumor antigen-encod-
ing genes into professional antigen-presenting cells. Tumor
cells can be engineered to express MHC class I and class II,
costimulatory molecules, or cytokines, and used as vac-
cines. Several gene therapy applications to induce antitu-
mor immunity have been reported for pediatric cancer
patients in preliminary phase I studies [9].
Current research also focuses on vaccinating directly
with antigen-encoding DNA. Studies in animal models
have demonstrated the feasibility of utilizing DNA vac-
cines to elicit protective cellular and humoral antitumor
immune responses [95]. In humans, DNA vaccines are
being tested in phase I to III clinical trials for cervical
cancer, melanoma, renal cell carcinoma, and prostate
cancer [80]. Preliminary results conWrm the safety and
immunogenicity of these vaccines. DNA vaccinations
have not been studied in pediatric patients. However,
Wrst steps are being taken with murine studies showing
that DNA-vaccination is potentially eVective to treat
neuroblastoma and prevent neuroblastoma metastases
[79, 97].
Tumor-associated antigens
One of the reasons for the paucity of clinical trials of thera-
peutic anti-cancer vaccination in children is the lack of
information about the expression of tumor-speciWc antigens
on many pediatric tumors. In the second part of this review
we will summarize the current data on the expression of
tumor antigens recognized by T cells on a selection of the
most common solid pediatric tumors.
Tumor antigens that can be recognized by T lympho-
cytes are complexes of HLA class I or class II molecules
presenting small antigenic peptides. The antigens can be
classiWed into four major groups, based on the pattern of
expression of the genes encoding the antigenic peptide
[14, 90].123
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These antigens are encoded by genes that are mutated in
tumor cells as compared to the normal cells of the patient;
the antigens can therefore be considered strictly tumor-
speciWc. The mutations can be point mutations, or translo-
cations, in genes that are expressed ubiquitously. The muta-
tion aVects a coding region of the gene, and antigenic
peptides contain mutated residues or straddle the junction
of chimeric proteins encoded by translocated genes.
Antigens encoded by cancer-germline genes
Cancer-germline genes are expressed in diVerent types of
human tumors. They are not expressed in normal tissues
with the exception of male germline cells which do not
express HLA molecules and therefore cannot present anti-
genic peptides to T cells [115]. For this reason the antigens
encoded by cancer-germline genes are strictly tumor-
speciWc.
DiVerentiation antigens
DiVerentiation antigens are encoded by lineage-speciWc
genes that are expressed in tumor cells as well as in the nor-
mal cells from which the tumor arises. The natural toler-
ance to these antigens is not complete, and the induction of
an immune response against diVerentiation antigens is
possible [35].
Antigens encoded by genes that are overexpressed
in tumors
This last group of tumor antigens is encoded by genes that
are overexpressed in tumors as compared to normal tissues.
Some oncogenes are expressed in normal tissues at a low
level and overexpressed in several tumors [17, 38]. Since
both diVerentiation antigens and overexpressed antigens are
expressed in normal tissues, autoimmunity can be a side
eVect when these antigens are used as immunotherapeutic
target.
T cell deWned antigens in pediatric solid tumors
For usefulness in immunotherapy, an antigen has to meet
two important criteria. It has to be expressed by the tumor
of the patient, and it has to be immunogenic. These criteria
can be tested with gene/protein expression and lymphocyte
recognition/tumor lysis assays (Fig. 2). For an eVective cel-
lular immune response, the tumor-speciWc antigen must be
processed into peptides and presented on HLA molecules.
Many tumor-associated antigens and epitopes have been
described that are recognized by CD4+ and/or CD8+ T cells.
Detailed lists of antigen-encoding genes and of epitopes
can be found at http://www.cancerimmunity.org.
Tables 1 and 2 summarize T cell deWned antigens on a
selection of the most important pediatric solid tumors. The
Fig. 2 In vitro assays to assess target suitability. a Immunohistochem-
istry of MAGE-1 expression in a neuroblastoma tumor (antibody
MA454) demonstrates the heterogeneous expression of MAGE-1 in
this tumor sample. b Visualization of MAGE-3 speciWc CD8+ cells us-
ing labeled CD8-Ab and A1/MAGE-3-tetramers. Dot plot of periphe-
ral blood mononuclear cells from a patient who received a vaccine
containing MAGE-3.A1 peptides. Twelve percent of the CD8+ cells
are tetramer-positive after 2 weeks of in vitro re-stimulation with the
MAGE-3.A1 peptide (EVDPIGHLY) [63]. c Chromium release assay
using cytotoxic T lymphocyte clone EH-1 B2.C10, which recognizes
peptide MAGE-3168¡176 presented by HLA-A1 molecules. Lysis was
tested after 4 h at 37°C, as previously described [12]. Only the HLA-
A1+, MAGE-3+ SK-N-SH neuroblastoma cell line (white dots) is
eYciently lysed by the CTL clone. Cell lines that are either HLA-A1
negative (IMR-32, black dots) or do not express gene MAGE-3 (EB81-
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tioned in the previous paragraph. To produce a clinically
relevant list, we have included only antigens of which (1)
peptides recognized by T cells are identiWed, (2) the HLA
presenting molecule is identiWed, (3) evidence exists that
the peptide is processed and presented by tumor cells, and
(4) a certain level of tumor- or tissue-speciWcity is reported.
Virus-encoded and artiWcially modiWed epitopes are
excluded from this list. Antigens of solid tumors outside the
central nervous system are shown in Table 1, and those of
brain tumors in Table 2. The percentages indicate the
proportions of tumors expressing the gene, tested with
RT-PCR or immunohistochemistry. Original papers are
only referred to if expression has been investigated in at
Table 1 T cell deWned antigens in extra-cranial pediatric solid tumors
The percentages indicate the proportion of tumors expressing the gene, tested with RT-PCR or IHC
GAGE G antigen, HER-2 human epidermal receptor 2, MAGE melanoma-associated antigen, ND not determined, NY-ESO-1 New York esopha-
gous 1, P53 protein 53, WT-1 Wilms’ tumor 1 gene
a Expression in alveolar rhabdomyosarcoma; no expression of MYCN in embryonal rhabdomyosarcoma
Antigen (refs) Neuroblastoma (%) Rhabdomyosarc. (%) Osteosarc. (%) Ewing’s sarc. (%)
Antigens from fusion proteins:
PAX3/FKHR [67] 0 60a 0 0
EWS/FLI 1 [31] 0 0 0 85
Cancer-germline genes: 82 9–16 ND 100
GAGE [20, 27]
MAGE-1 [25, 27, 52, 54, 117, 118] 18–60 25–38 55–88 0
MAGE-2 [21, 27, 54, 118] 60–61 33–51 55–78 0
MAGE-3 [25, 27, 52, 117, 118] 33–76 35–42 52–100 28
NY-ESO-1 [54, 104, 117] 36–82 25 88 0
Overexpressed antigens:
HER-2 [3, 41, 49, 83, 124, 139] 14 11 0–44 0
MYCN [33, 46, 130] 20–25 43–60a ND ND
P53 [3, 6, 28, 91, 121, 124, 126] 84 19–67 14–27 11–43
Survivin [1, 53, 122] 47–54 ND 58 ND
Table 2 T cell deWned antigens in pediatric brain tumors
The percentages indicate the proportion of tumors expressing the gene, tested with RT-PCR or IHC
GAGE G antigen, gp100 glycoprotein 100, HER-2 human epidermal receptor 2, IL interleukin, MAGE melanoma-associated antigen, ND not deter-
mined, NY-ESO-1 New York esophagous 1, P53 protein 53, WT-1 Wilms’ tumor 1 gene
Antigen (refs) Low grade astrocytoma (%) High grade astrocytoma (%) Ependymoma (%) Medulloblastoma (%)
Cancer-germline genes:
GAGE [110] ND 11 43 13
MAGE-1 [11, 22, 57, 102, 110] 0–33 0–100 0 9–13
MAGE-2 [57, 110] 12–18 10–11 57 18–60
MAGE-3 [22, 57, 108, 110] 18–35 20–33 0–33 13–18
NY-ESO-1 [57, 108] 0–14 0–10 ND 9
Overexpressed antigens:
HER-2 [44, 45, 77, 111] 0–77 5–93 83 38–86
IL-13R [59, 65] 79 100 67 67–100
MYCN [2, 8, 50, 71] ND 43 ND 5–21
P53 [58, 69, 73, 85, 132] 8–72 52–63 28–48 17–27
Survivin [60, 64, 92, 109] 37–64 80–92 100 100
WT-1 [32] 40 56 56 39
DiVerentiation antigens:
Tyrosinase [22] 67 38 50 ND
Gp100 [22, 77] 33 38–47 50 ND123
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to the year of publication.
All tumors reviewed here, except neuroblastoma, also
occur in adults. Most papers about antigen expression do
not report whether tumor samples are derived from adults
or children. Only a few papers speciWcally report on antigen
expression in pediatric tumors [44, 54, 57, 65, 73, 85, 92].
It is important to note that the expression of a given antigen
in tumors of adult patients does not guarantee that this anti-
gen is also expressed in the tumor of that same subtype
from a pediatric patient. We and others observed signiWcant
age-related diVerences in the expression of tumor antigens
in glioblastoma samples [57, 92, 100, 120]. For some anti-
gens we noticed important diVerences in the expressions
reported by diVerent groups. They can be due to the sensi-
tivity/speciWcity of the techniques used (microarray, RT-
PCR and immunohistochemistry), to diVerent antibodies or
primer-pairs for the same antigen, and to diVerently chosen
cut-oV points.
Which antigens to choose for pediatric clinical trials?
Table 1 and 2 list T cell deWned antigens expressed on pedi-
atric tumors that can be used as immune target in clinical
trials. So far, these antigens have primarily been used in
clinical trials in adult patients with the exception of clinical
trials in pediatric patients targeting the following antigens:
PAX3/FKHR and EWS/FLI1 [26, 82], WT-1 (ongoing
clinical trial, http://www.clinicaltrials.gov) and MAGE-A1
(Jacobs et al., manuscript in preparation). Choosing the best
antigen in a speciWc immunotherapy trial depends on the
individual needs for that study such as the immunogenicity
of the antigen, the level of antigen expression by the
tumors, the tumor-speciWcity of the antigen, the availability
of clinical grade antigenic products, and the HLA-type of
the included patients.
Mutated tumor antigens are attractive antigens for can-
cer immunotherapy because of their strict tumor-speciWc-
ity and because of their potential resistance to
immunoselection when the mutated gene product plays an
important role in the oncogenic process. One drawback is
that most point mutations, in contrast to chromosomal
translocations, are not shared by tumors from diVerent
patients. Examples of chimeric proteins in the pediatric
setting are the PAX3-FKHR, EWS-FLI 1, TEL-AML1,
and BCR-ABL fusion proteins seen in alveolar rhabdo-
myosarcoma, Ewing’s sarcoma, acute lymphatic leuke-
mia, and chronic myeloid leukemia, respectively [18, 81,
129, 137]. For all four fusion proteins several MHC class
I and class II chimeric peptides have been described that
induce speciWc T cells and can be considered for immuno-
therapy [82, 136–138].
The other genetic mechanism responsible for tumor-
speciWcity of antigens is the aberrant expression in tumor
cells of genes that are silent in normal cells. When the anti-
gens are encoded by genes that are expressed in many
diVerent tumors they are called ‘shared tumor-speciWc anti-
gens’. Most of the shared tumor-speciWc antigens are
encoded by cancer-germline genes. Cancer-germline genes
such as MAGE, GAGE, or LAGE/NY-ESO-1, are
expressed in diVerent types of pediatric tumors (Tables 1,
2). Numerous peptides, binding to diVerent HLA class I and
HLA class II molecules have been identiWed [15]. Because
of their tumor-speciWcity and immunogenic potential, anti-
gens encoded by cancer-germline genes have been one of
the main components of antitumor vaccines tested in the
clinic during the last decade [115].
Approximately 20% of all identiWed tumor antigens are
encoded by genes that are overexpressed in cancer cells as
compared to normal cells. Overexpression in this context
means more antigenic peptides presented on MHC mole-
cules at the cell surface, explaining the tumor-speciWcity of
the T lymphocytes. As shown in Tables 1 and 2, many of
the identiWed antigens in pediatric solid tumors are classi-
Wed as overexpressed antigens. HER-2, WT-1, and MYCN
are the most interesting candidates for immunotherapy
since these genes are involved in cell proliferation and
their overexpression plays a direct functional role in tumor
progression. This role in oncogenesis implies that it is
more diYcult for the tumor to escape immune attack
through downregulation of antigen expression. The
absence of autoimmune tissue damage in cancer patients
with HER-2, WT-1, or MYCN speciWc CTLs suggests that
these antigens can be safely used as immunotherapeutic
target [5, 7, 48].
With the observation that tumor-speciWc CTL clones
derived from melanoma patients could also recognize nor-
mal melanocytes it became obvious that natural tolerance
to diVerentiation antigens was incomplete [4]. Gp100 and
tyrosinase are the only diVerentiation antigens expressed
in pediatric tumors for which T cell speciWc peptides are
identiWed (Table 2). Autoimmunity can be a side eVect
when diVerentiation antigens are used for vaccination.
Since gp100 and tyrosinase are expressed in normal mela-
nocytes, it is possible that pediatric patients will develop
vitiligo when these antigens are used in a vaccine [56,
127].
For safety concern, the target antigens used in pediat-
ric clinical trials should be strictly tumor-speciWc. If
such an antigen is not available, the normal tissue
expressing the antigen must be dispensable, to avoid
serious autoimmune toxicity. Finally, it is probably pref-
erable to use combinations of antigens to decrease the
probability of in vivo selection of antigen-negative
tumor cells.123
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Immunotherapy against cancer is a Weld of growing inter-
est. Most therapies are still experimental and focus on adult
patients. However, the Wrst immunotherapeutic trials for
pediatric cancer patients have been published, and more are
ongoing. These novel trials aim at stimulating both humoral
and cellular anti-tumor immune responses. The identiWca-
tion of many tumor-associated antigens, including for most
pediatric solid tumor types, should facilitate this clinical
endeavor.
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